Atea Pharmaceuticals completes enrollment in phase 3 HCV trial

June 25, 2026 7:01 AM

Atea Pharmaceuticals (NASDAQ: AVIR) announced it has completed patient enrollment in its C-FORWARD Phase 3 clinical trial evaluating a fixed-dose ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found